The sale is part of Novo Nordisk’s proposed acquisition of Catalent, a contract development and manufacturing organization based in Somerset, N.J. The three facilities are in Italy, Belgium and Bloomington, Ind., and employ more than 3,000 people, according to a Feb. 5 news release.
The facilities are equipped for sterile filling, and Novo Nordisk said the fill-finish sites will focus on increasing supply of its diabetes and obesity treatments starting in 2026.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
